Literature DB >> 26334681

Structure of neurotropic adeno-associated virus AAVrh.8.

Sujata Halder1, Kim Van Vliet1, J Kennon Smith1, Thao Thi Phuong Duong1, Robert McKenna1, James M Wilson2, Mavis Agbandje-McKenna3.   

Abstract

Adeno-associated virus rhesus isolate 8 (AAVrh.8) is a leading vector for the treatment of neurological diseases due to its efficient transduction of neuronal cells and reduced peripheral tissue tropism. Toward identification of the capsid determinants for these properties, the structure of AAVrh.8 was determined by X-ray crystallography to 3.5 Å resolution and compared to those of other AAV isolates. The capsid viral protein (VP) structure consists of an αA helix and an eight-stranded anti-parallel β-barrel core conserved in parvoviruses, and large insertion loop regions between the β-strands form the capsid surface topology. The AAVrh.8 capsid exhibits the surface topology conserved in all AAVs: depressions at the icosahedral twofold axis and surrounding the cylindrical channel at the fivefold axis, and three protrusions around the threefold axis. A structural comparison to serotypes AAV2, AAV8, and AAV9, to which AAVrh.8 shares ∼ 84%, ∼ 91%, and ∼ 87% VP sequence identity, respectively, revealed differences in the surface loops known to affect receptor binding, transduction efficiency, and antigenicity. Consistent with this observation, biochemical assays showed that AAVrh.8 is unable to bind heparin and does not cross-react with conformational monoclonal antibodies and human donor serum directed against the other AAVs compared. This structure of AAVrh.8 thus identified capsid surface differences which can serve as template regions for rational design of vectors with enhanced transduction for specific tissues and escape pre-existing antibody recognition. These features are essential for the creation of an AAV vector toolkit that is amenable to personalized disease treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV vectors; Capsid structure; Gene therapy; Neurotropism; Parvovirus; X-ray crystallography

Mesh:

Substances:

Year:  2015        PMID: 26334681      PMCID: PMC4617535          DOI: 10.1016/j.jsb.2015.08.017

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  114 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

2.  Assessment of phase accuracy by cross validation: the free R value. Methods and applications.

Authors:  A T Brünger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1993-01-01

3.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

5.  Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.

Authors:  Stephan Maersch; Anke Huber; Hildegard Büning; Michael Hallek; Luca Perabo
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

6.  Canine parvovirus capsid structure, analyzed at 2.9 A resolution.

Authors:  Q Xie; M S Chapman
Journal:  J Mol Biol       Date:  1996-12-06       Impact factor: 5.469

7.  Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6).

Authors:  Qing Xie; Thomas F Lerch; Nancy L Meyer; Michael S Chapman
Journal:  Virology       Date:  2011-09-13       Impact factor: 3.616

8.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  The structure of AAVrh32.33, a novel gene delivery vector.

Authors:  Kyle Mikals; Hyun-Joo Nam; Kim Van Vliet; Luk H Vandenberghe; Lauren E Mays; Robert McKenna; James M Wilson; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2014-04-02       Impact factor: 2.867

View more
  18 in total

1.  Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2.

Authors:  Antonette Bennett; Annahita Keravala; Victoria Makal; Justin Kurian; Brahim Belbellaa; Rangoli Aeran; Yu-Shan Tseng; Duncan Sousa; John Spear; Mehdi Gasmi; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2019-12-16       Impact factor: 2.867

Review 2.  Cryo-electron Microscopy of Adeno-associated Virus.

Authors:  Scott M Stagg; Craig Yoshioka; Omar Davulcu; Michael S Chapman
Journal:  Chem Rev       Date:  2022-05-16       Impact factor: 72.087

3.  Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity.

Authors:  Mario Mietzsch; Joshua A Hull; Victoria E Makal; Alberto Jimenez Ybargollin; Jennifer C Yu; Kedrick McKissock; Antonette Bennett; Judit Penzes; Bridget Lins-Austin; Qian Yu; Paul Chipman; Nilakshee Bhattacharya; Duncan Sousa; David Strugatsky; Peter Tijssen; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2022-05-09       Impact factor: 6.549

4.  Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.

Authors:  Lauren M Drouin; Bridget Lins; Maria Janssen; Antonette Bennett; Paul Chipman; Robert McKenna; Weijun Chen; Nicholas Muzyczka; Giovanni Cardone; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 5.  Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.

Authors:  Michael E Nance; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2015-10-15       Impact factor: 5.695

6.  Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function.

Authors:  April R Giles; Joshua J Sims; Kevin B Turner; Lakshmanan Govindasamy; Mauricio R Alvira; Martin Lock; James M Wilson
Journal:  Mol Ther       Date:  2018-10-18       Impact factor: 11.454

7.  Adeno-associated Virus 9 Structural Rearrangements Induced by Endosomal Trafficking pH and Glycan Attachment.

Authors:  Judit J Penzes; Paul Chipman; Nilakshee Bhattacharya; Allison Zeher; Rick Huang; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2021-07-14       Impact factor: 5.103

8.  Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy.

Authors:  Sanford L Boye; Shreyasi Choudhury; Sean Crosson; Giovanni Di Pasquale; Sandra Afione; Russell Mellen; Victoria Makal; Kaitlyn R Calabro; Diego Fajardo; James Peterson; Hangning Zhang; Matthew T Leahy; Colin K Jennings; John A Chiorini; Ryan F Boyd; Shannon E Boye
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 12.910

9.  Crystal Structure of Major Envelope Protein VP24 from White Spot Syndrome Virus.

Authors:  Lifang Sun; Yintao Su; Yanhe Zhao; Zheng-Qing Fu; Yunkun Wu
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

10.  Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes.

Authors:  Shelley A Nass; Maryellen A Mattingly; Denise A Woodcock; Brenda L Burnham; Jeffrey A Ardinger; Shayla E Osmond; Amy M Frederick; Abraham Scaria; Seng H Cheng; Catherine R O'Riordan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-12-22       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.